Cornell’s Research
Serves the Region and Beyond

XyloCor Therapeutics, Inc. CTL

Biopharmaceuticals: Cardiovascular Disease/Gene Therapy

  • Products:
  • XC001
  • XC002

XyloCor Therapeutics is a biopharmaceutical company developing gene therapy for people with advanced coronary artery disease.  The company is focused on developing its lead product, XC001, for patients with refractory angina with no treatment options. Its secondary product, XC002, is for patients with cardiac tissue damage from heart attacks. The company’s five year goals include successful clinical trials and the launch of XC001.

Cornell Connection

XyloCor Therapeutics was founded by a professor at Weill Cornell Medicine. The foundational technology is licensed from Cornell University.